Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
Background: With the increasing disease burden of cancer worldwide, more and more anticancer drugs have been approved in many countries, and the results of budget impact analyses (BIAs) have become important evidence for related reimbursement decisions.Objectives: We systematically reviewed whether...
Saved in:
Main Authors: | Yue Ma (Author), Yuxin Li (Author), Aixia Ma (Author), Hongchao Li (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis
by: Donger Zhang, et al.
Published: (2021) -
Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022) -
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022) -
Medication adherence with fixed-dose versus free-equivalent combination therapies: Systematic review and meta-analysis
by: Qiran Wei, et al.
Published: (2023) -
Economic Burden of Myocardial Infarction Combined With Dyslipidemia
by: Pingyu Chen, et al.
Published: (2021)